



FORM 13

(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
 SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : K. Lalngilneia
Asst. Director (F&D)
CMO Office, Mamit District: Mamit, Pin- 796441
- Serial No. and date of Inspector's memorandum : B.17011/12/09-CMO (M)/DRUGS/22 Date 27th Nov,24
- Number of Sample :MD08/22
- Date of receipt :09-DEC-2024
- Names of drugs purporting to be contained in the sample: Cefixime Dispersible Tablets IP (Cefime O 200 Tablets)

| Lab. Sample No. | Report No. | Batch No. | Date of Mfg. | Date of Exp. | Mfg. By |
|----------------------|---------------------|-----------|--------------|--------------|------------------------------------------------------------------------------|
| LSD/GUW/2024-25/1462 | GUW/LS/2024-25/1488 | SPT-36186 | 08/2023 | 07/2025 | Shervotec Pharmaceuticals, 82/4&82/5,HPSIDC,Baddi, Distt, Solana (H.P) |

6. Condition of seals on [the packet or on portion of sample or container] : Seals were intact & identical to the Specimen impression of the seal received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied :Please see below

Date of Testing : From 24-Dec-2024 To 02-Jan-2025

COMPOSITION : Each uncoated dispersible tablet contains:
 Cefixime Trihydrate IP
 Eq. to Cefixime (Anhydrous) 200 mg.

Protocol Applied: I.P. 2022

| Sr No. | Test Name | Result | Limits |
|--------|--------------------------|----------------------------------------------------------------------------------------|---------------|
| 1 | Description | Orange colour, round, bi-convex, uncoated dispersible tablet in aluminum blister pack. | NA |
| 2 | Identification | Gives positive test for Cefixime. | NA |
| 3 | Average weight | 0.3019 gm. | NA |
| 4 | Uniformity of weight | Complies. | NA |
| 5 | Uniformity of dispersion | Complies. | NA |
| 6 | Disintegration | Complies (All six units disintegrated within 28 seconds). | NMT 3 minutes |

Assay

| Sr.No | Ingredient Name | Found | Claim | % of claim | Limits | Procedure / Method |
|-------|-----------------|-------|-------|------------|--------|--------------------|
| | | | | | | |

| | | | | | | |
|---|-----------------------------------------------|------------------|---------------|-------|---------------|-----------|
| 1 | Cefixime Trihydrate Eq. to Anhydrous Cefixime | 197.06 mg/Tablet | 200 mg/Tablet | 98.53 | 90 % to 110 % | I.P. 2022 |
|---|-----------------------------------------------|------------------|---------------|-------|---------------|-----------|

In the opinion of the under signed the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules thereunder for the reasons given below:-

The sample conforms to I.P. with respect to the above tests only.

Date: 03-JAN-2025



GOVERNMENT ANALYST
Dilip Kr. Sarkar
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

